Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Somatostatin analog
Lanreotide
Somatuline · LAN
Long-acting somatostatin analog for GEP-NETs; generally kidney-neutral with only mild electrolyte effects and reduced clearance in severe renal impairment.
Mildestablished · approved 2007
Unresectable/locally advanced or metastatic well- or moderately-differentiated, nonfunctioning or functioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Carcinoid syndrome symptom controlAcromegaly
Signature kidney injury
Electrolyte Wasting
No characteristic intrinsic nephrotoxicity; lanreotide is generally kidney-neutral. Renal adverse events are not a defining feature and are not reliably quantified; mild electrolyte effects are uncommon.
Source: Caplin et al., NEJM 2014 (CLARINET; diarrhea-dominant, kidney-neutral)
Mechanism of kidney injury
Lanreotide has no established direct nephrotoxic mechanism. Renal relevance is pharmacokinetic: the drug is partly renally eliminated, so systemic exposure increases and clearance falls in moderate-to-severe renal impairment, but this reflects accumulation rather than tubular/glomerular injury. Antisecretory hormonal actions can rarely contribute to mild electrolyte or glycemic shifts. In the CLARINET pivotal trial the dominant adverse event was diarrhea, not kidney injury.
Clinical presentation
Usually no renal findings. When relevant, presentation is mild: occasional electrolyte or glucose disturbance from hormonal effects, or volume-related changes secondary to GI symptoms (diarrhea). Severe renal impairment manifests as increased drug exposure rather than new kidney pathology.
Onset
Not applicable for intrinsic injury; exposure rises gradually in renal impairment.
Reversibility
Reversible
Anticancer mechanism
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 (and SSTR5) that suppresses secretion of growth hormone and gut/pancreatic hormones and exerts a direct antiproliferative effect on well-differentiated neuroendocrine tumors, prolonging progression-free survival in enteropancreatic NETs.
Management
No renal-specific management is generally required. In significant renal impairment, anticipate higher exposure and monitor for dose-related adverse effects. Manage electrolyte/glucose changes supportively; treat underlying tumor.
Risk factors
- Severe chronic kidney disease or dialysis (reduced clearance/increased exposure)
- Volume depletion from secretory diarrhea
- Baseline electrolyte derangement from functioning tumors
Prevention
- Recognize kidney-neutral profile; routine renal-specific prophylaxis not required at normal function
- Account for increased exposure in severe renal impairment
- Maintain euvolemia and replace losses in patients with diarrhea
Note · Reported use of lanreotide (with everolimus) in a hemodialysis patient with metastatic carcinoid supports feasibility in advanced renal failure with appropriate caution.
Clinical depth
Renal dose adjustment
Exposure increases with the degree of renal impairment; some labeling recommends a reduced starting dose in moderate-to-severe renal impairment for certain indications. Consult product information for the specific formulation and indication.
Dialyzability & ESKD dosing
Not established as meaningfully dialyzable for supplemental dosing; depot peptide pharmacology and case experience suggest cautious use in hemodialysis without routine post-dialysis supplementation.
Differential diagnosis
Electrolyte or volume disturbance in a NET patient on lanreotide more likely reflects secretory diarrhea or paraneoplastic hormone effects than a primary tubular lesion; consider concomitant nephrotoxins (e.g., everolimus, contrast) before attributing AKI to lanreotide.
Monitoring
- Serum electrolytes and volume status, especially with diarrhea
- Blood glucose (altered insulin/glucagon secretion)
- Gallbladder/biliary status with chronic use
- Renal function in advanced CKD to gauge exposure
Key trials & series
- CLARINET (Caplin et al., NEJM 2014): lanreotide Autogel 120 mg prolonged PFS vs placebo in metastatic enteropancreatic NETs; most common adverse event diarrhea, not nephrotoxicity
- Hemodialysis case of everolimus + lanreotide for metastatic atypical bronchial carcinoid (Brizzi et al., BMC Cancer 2018)
Clinical pearls
- Kidney-neutral somatostatin analog — think exposure/accumulation in CKD, not intrinsic toxicity.
- CLARINET established its antiproliferative benefit in GEP-NETs; diarrhea, not renal injury, dominated the safety profile.
- Mild electrolyte/glucose effects derive from broad antisecretory hormonal action.
- Feasible in hemodialysis with caution per case reports.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
Electrolyte WastingPrerenal / Hemodynamic AKI
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkLanreotide in metastatic enteropancreatic neuroendocrine tumors.Caplin ME et al. · N Engl J Med 2014 · PMID 25014687CLARINET pivotal RCT establishing efficacy and overall safety profile (dominant AE diarrhea, not nephrotoxicity), supporting a kidney-neutral characterization.PMIDEfficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.Brizzi MP et al. · BMC Cancer 2018 · PMID 29558899Documents lanreotide use combined with everolimus in a hemodialysis patient, illustrating tolerability of the somatostatin analog in end-stage renal disease.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med 2017 · PMID 28467867Onconephrology framework for distinguishing indirect/electrolyte effects and drug accumulation in CKD from intrinsic anticancer-drug nephrotoxicity.